Chimeric antigen receptor T (CAR-T) cell therapy is regarded as an effective solution for
relapsed or refractory tumors, particularly for hematological malignancies. Although the …

T cells engineered to express chimeric antigen receptors (CARs) with tumor specificity have
shown remarkable success in treating patients with hematologic malignancies and …

Chimeric antigen receptor (CAR) T cell therapies have evolved from a research tool to a
concept-shifting therapy with impressive responses in B cell malignancies. This Review …

T cells genetically engineered to express chimeric antigen receptors (CARs) have proven—
and impressive—therapeutic activity in patients with certain subtypes of B cell leukaemia or …

Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary new pillar in cancer
treatment. Although treatment with CAR-T cells has produced remarkable clinical responses …

Chimeric antigen receptor (CAR) T cell therapy has shown promising efficacy against
hematologic malignancies. Antitumor activity of CAR T cells, however, needs to be improved …

The focus of cancer treatment has recently shifted toward targeted therapies, including
immunotherapy, which allow better individualization of care and are hoped to increase the …

T cells engineered to express chimeric antigen receptors (CARs) that are specific for tumour
antigens have led to high complete response rates in patients with haematologic …

Chimeric antigen receptor (CAR) T cells are engineered constructs composed of synthetic
receptors that direct T cells to surface antigens for subsequent elimination. Many CAR …

T cells genetically targeted with a chimeric antigen receptor (CAR) to B-cell malignancies
have demonstrated tremendous clinical outcomes. With the proof in principle for CAR T cells …